The total number of records retrieved from this search are 100. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_897	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for Hep 3B cancer cell line	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor nodes after 4 weeks	Mode of deliveryintraperitonial	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12788648
IDOV_916	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/cByJIcrSmnHsd-scid mice orthotopic xenograft for prostate cancer cell line	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo result30% reduction in tumor volume	Mode of deliveryTail vein injection of virus	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_917	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/cByJIcrSmnHsd-scid mice orthotopic xenograft for prostate cancer cell line	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo result50% reduction in tumor volume	Mode of deliveryTail vein injection of virus	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_918	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/cByJIcrSmnHsd-scid mice orthotopic xenograft for prostate cancer cell line	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo result60% reduction in tumor volume	Mode of deliveryTail vein injection of virus	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_919	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/cByJIcrSmnHsd-scid mice metastatic lung metastatic model	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultLung metastasis were not detected after 40 days when stained with bouins fixative	Mode of deliveryTail vein injection of virus	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_920	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/cByJIcrSmnHsd-scid mice metastatic lung metastatic model	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultLung metastasis were not detected after 40 days when stained with bouins fixative	Mode of deliveryTail vein injection of virus	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_921	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/cByJIcrSmnHsd-scid mice metastatic lung metastatic model	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultLung metastasis were not detected after 40 days when stained with bouins fixative	Mode of deliveryTail vein injection of virus	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_1915	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMalignan small cell canine carcinoma cell line	Cell lineMTH52c	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for MTH52c cell line	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultSignificant decrease in tumor volume after 42 days	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus cause increase expression of ApoA1, IL-2,11,18,IFN-gamma, IP-10, MCP-1,3,5,MIP-2,MMP-9 and TNF alpha	Clinical trialNA	PMID20631910
IDOV_2063	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic hsd nude mice xenograft for PLC cell line	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityReduction in tumor volume below 2000mm compared to control after 45 days	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer cell line	Immunogenic effectIncreased expression of immunological gene such as GM-CSF, IFN-gamma, IL-6,2,12,18, IP-10, MCP-1,3,5, TNF-alpha and MIP-2	Clinical trialNA	PMID21779374
IDOV_2064	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHuh-7	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic hsd nude mice xenograft for PLC cell line	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityReduction in tumor volume below 3000mm compared to control after 35 days	In-vivo result	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer cell line	Immunogenic effectIncreased expression of immunological gene such as GM-CSF, IFN-gamma, IL-6,2,12,18, IP-10, MCP-1,3,5, TNF-alpha and MIP-2	Clinical trialNA	PMID21779374
IDOV_2526	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd:athymic nude mice xenografted for PANC-1 cell line(2.0E+6 cells)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultDecrease in tumor volume below 2 after 34 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2527	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd:athymic nude mice xenografted for PANC-1 cell line(2.0E+6 cells)	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultDecrease in tumor volume below 2 after 34 days	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2843	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd:athymic nude mice xenograft for HCT-116 (5.0E+6 cells)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume after 42 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23531320
IDOV_3002	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd:athymic nude mice xenograft for HCT-116 (2.0E+6 cells)	In-vivo virus concentration1.0E+5 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume after 55 days	Mode of deliveryIntratumoral	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_3003	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd:athymic nude mice xenograft for HT-29 (5.0E+6 cells)	In-vivo virus concentration1.0E+5 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reached 1500mm after day 50	Mode of deliveryIntratumoral	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_3004	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with I-131	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd:athymic nude mice xenograft for HCT-116 (2.0E+6 cells)	In-vivo virus concentration1.0E+4 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume below 100mm after 55 days	Mode of deliveryIntravenous	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_3005	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with I-131	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd:athymic nude mice xenograft for HT-29 (3.0E+9 cells)	In-vivo virus concentration1.0E+4 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume below 300mm after 45 days	Mode of deliveryIntravenous	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_4108	Virus nameVaccinia virus	Virus strainVVstrain LIVP 6.1.1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationMutant for J2R gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of colorado, USA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for STSA-1 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 1000 mm compared to control 2500mm after 42 days	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4109	Virus nameVaccinia virus	Virus strainVVstrain GLV-5b451	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDerived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of colorado, USA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for STSA-1 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 200 mm compared to control 2500mm after 49 days	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_5682	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 261.8mm compared to control 240.8 mm after 33 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5683	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 248.4mm compared to control 240.8 mm after 33 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5684	Virus nameVaccinia virus	Virus strainGLV-1h70	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, LacZ gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 216.8mm compared to control 240.8 mm after 33 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5685	Virus nameVaccinia virus	Virus strainGLV-1h71	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 208.8mm compared to control 240.8 mm after 33 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5686	Virus nameVaccinia virus	Virus strainGLV-1h72	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA and LacZ at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 157.2mm compared to control 240.8 mm after 33 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5687	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 280.3mm compared to control 240.8 mm after 33 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5688	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 301.9mm compared to control 240.8 mm after 33 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5689	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 273.5mm compared to control 263.6 mm after 36 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5690	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 243.8mm compared to control 263.6 mm after 36 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5691	Virus nameVaccinia virus	Virus strainGLV-1h70	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, LacZ gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 286mm compared to control 263.6 mm after 36 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5692	Virus nameVaccinia virus	Virus strainGLV-1h71	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 267.1mm compared to control 263.6 mm after 36 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5693	Virus nameVaccinia virus	Virus strainGLV-1h72	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA and LacZ at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 155.6mm compared to control 263.6 mm after 36 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5694	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 310.9mm compared to control 263.6 mm after 36 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5695	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 416.9mm compared to control 263.6 mm after 36 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5696	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 536.1mm compared to control 579.1 mm after 43 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5697	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 5550.4mm compared to control 579.1 mm after 43 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5698	Virus nameVaccinia virus	Virus strainGLV-1h70	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, LacZ gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 463.4mm compared to control 579.1 mm after 43 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5699	Virus nameVaccinia virus	Virus strainGLV-1h71	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 543.3mm compared to control 579.1 mm after 43 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5700	Virus nameVaccinia virus	Virus strainGLV-1h72	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA and LacZ at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 320.1mm compared to control 579.1 mm after 43 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5701	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 679mm compared to control 579.1 mm after 43 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5702	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 660mm compared to control 579.1 mm after 43 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5703	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 701.4mm compared to control 636.4 mm after 50 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5704	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 761.3mm compared to control 636.4 mm after 50 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5705	Virus nameVaccinia virus	Virus strainGLV-1h70	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, LacZ gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 706.6mm compared to control 636.4 mm after 50 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5706	Virus nameVaccinia virus	Virus strainGLV-1h71	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 721.3mm compared to control 636.4 mm after 50 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5707	Virus nameVaccinia virus	Virus strainGLV-1h72	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA and LacZ at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 476.3mm compared to control 636.4 mm after 50 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5708	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 864.1mm compared to control 636.4 mm after 50 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5709	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 828.6mm compared to control 636.4 mm after 50 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5710	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 978.4mm compared to control 671.6 mm after 57 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5711	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 852mm compared to control 671.6 mm after 57 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5712	Virus nameVaccinia virus	Virus strainGLV-1h70	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, LacZ gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 985.5mm compared to control 671.6 mm after 57 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5713	Virus nameVaccinia virus	Virus strainGLV-1h71	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 936.1mm compared to control 671.6 mm after 57 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5714	Virus nameVaccinia virus	Virus strainGLV-1h72	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA and LacZ at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 695mm compared to control 671.6 mm after 57 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5715	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 1179.9mm compared to control 671.6 mm after 57 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5716	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 897.4mm compared to control 671.6 mm after 57 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5717	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 1485mm compared to control 2715 mm after 92 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5718	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 1053mm compared to control 2715 mm after 92 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5719	Virus nameVaccinia virus	Virus strainGLV-1h70	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, LacZ gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 852mm compared to control 2715 mm after 92 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5720	Virus nameVaccinia virus	Virus strainGLV-1h71	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 606mm compared to control 2715 mm after 92 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5721	Virus nameVaccinia virus	Virus strainGLV-1h72	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA and LacZ at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 751mm compared to control 2715 mm after 92 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5722	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 166.7mm compared to control 2715 mm after 92 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5723	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume after 92 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5724	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 1536.9mm compared to control 2918.3 mm after 97 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5725	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 962.2mm compared to control 2918.3 mm after 97 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5726	Virus nameVaccinia virus	Virus strainGLV-1h70	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, LacZ gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 579.2mm compared to control 2918.3 mm after 97 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5727	Virus nameVaccinia virus	Virus strainGLV-1h71	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 546.9mm compared to control 2918.3 mm after 97 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5728	Virus nameVaccinia virus	Virus strainGLV-1h72	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA and LacZ at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 720.1mm compared to control 2918.3 mm after 97 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5729	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 117.8mm compared to control 2918.3 mm after 97 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5730	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume after 97 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5731	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 412.9mm after 39 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5732	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 350.2mm after 39 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5733	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 341.1mm after 39 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5734	Virus nameVaccinia virus	Virus strainGLV-1h82	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of HA gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 353.4mm after 39 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5735	Virus nameVaccinia virus	Virus strainGLV-1h83	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of HA gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 392.25mm after 39 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5736	Virus nameVaccinia virus	Virus strainGLV-1h84	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of F14.5L gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 305.6mm after 39 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5737	Virus nameVaccinia virus	Virus strainGLV-1h85	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA into F14.5L gene, TK gene at place of LacZ and gusA gene at place of HA gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 350.65mm after 39 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5738	Virus nameVaccinia virus	Virus strainGLV-1h86	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP into F14.5L gene, noncoding DNA at place of LacZ and HA gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 419.55mm after 39 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5739	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 750.4mm after 47 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5740	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 722.3mm after 47 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5741	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 819.8mm after 47 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5742	Virus nameVaccinia virus	Virus strainGLV-1h82	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of HA gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1081.2mm after 47 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5743	Virus nameVaccinia virus	Virus strainGLV-1h83	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of HA gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1222.25mm after 47 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5744	Virus nameVaccinia virus	Virus strainGLV-1h84	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of F14.5L gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 604.3mm after 47 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5745	Virus nameVaccinia virus	Virus strainGLV-1h85	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA into F14.5L gene, TK gene at place of LacZ and gusA gene at place of HA gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 914mm after 47 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5746	Virus nameVaccinia virus	Virus strainGLV-1h86	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP into F14.5L gene, noncoding DNA at place of LacZ and HA gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 962.1mm after 47 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5747	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1424.4mm after 62 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5748	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1390.35mm after 62 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5749	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 983.2mm after 62 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5750	Virus nameVaccinia virus	Virus strainGLV-1h82	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of HA gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1319.2mm after 62 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5751	Virus nameVaccinia virus	Virus strainGLV-1h83	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of HA gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1686.05mm after 62 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5752	Virus nameVaccinia virus	Virus strainGLV-1h84	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of F14.5L gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 982mm after 62 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5753	Virus nameVaccinia virus	Virus strainGLV-1h85	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA into F14.5L gene, TK gene at place of LacZ and gusA gene at place of HA gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 947.2mm after 62 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5754	Virus nameVaccinia virus	Virus strainGLV-1h86	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP into F14.5L gene, noncoding DNA at place of LacZ and HA gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1397.55mm after 62 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5755	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1907.5mm after 75 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5756	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1528.95mm after 75 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5757	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 517.3mm after 75 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5758	Virus nameVaccinia virus	Virus strainGLV-1h82	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of HA gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1211.8mm after 75 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5759	Virus nameVaccinia virus	Virus strainGLV-1h83	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of HA gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1856.35mm after 75 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5760	Virus nameVaccinia virus	Virus strainGLV-1h84	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of F14.5L gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 614.25mm after 75 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5761	Virus nameVaccinia virus	Virus strainGLV-1h85	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA into F14.5L gene, TK gene at place of LacZ and gusA gene at place of HA gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 255.25mm after 75 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5762	Virus nameVaccinia virus	Virus strainGLV-1h86	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP into F14.5L gene, noncoding DNA at place of LacZ and HA gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 689.6mm after 75 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968